Document is current
Any future updates will be listed below
-
Authors
Nokin, Marie-Julie
Mira, Alessia
Patrucco, Enrico https://orcid.org/0000-0001-8060-5058
Ricciuti, Biagio
Cousin, Sophie
Soubeyran, Isabelle
San José, Sonia
Peirone, Serena https://orcid.org/0000-0002-5195-7908
Caizzi, Livia
Vietti Michelina, Sandra
Bourdon, Aurelien
Wang, Xinan
Alvarez-Villanueva, Daniel
Martínez-Iniesta, María https://orcid.org/0000-0001-6252-6671
Vidal, August https://orcid.org/0000-0001-5727-2099
Rodrigues, Telmo
García-Macías, Carmen https://orcid.org/0000-0002-5929-4926
Awad, Mark M.
Nadal, Ernest https://orcid.org/0000-0002-9674-5554
Villanueva, Alberto https://orcid.org/0000-0001-5164-0006
Italiano, Antoine https://orcid.org/0000-0002-8540-5351
Cereda, Matteo https://orcid.org/0000-0003-1799-5537
Santamaría, David https://orcid.org/0000-0002-4711-3569
Ambrogio, Chiara https://orcid.org/0000-0003-4122-701X
- License Information
-
More Information
Article History
Received: 21 November 2023
Accepted: 20 August 2024
First Online: 30 August 2024
Competing interests
: The authors declare the following competing interests: D.S. received research fees from Aelin Therapeutics. C.A. received research fees from Revolution Medicines, Aelin Therapeutics, Verastem, Roche, and Boehringer Ingelheim. A.I. received research support from AstraZeneca, Bayer, BMS, Merck, MSD, Pharmamar, and Roche and participated as a consultant in advisory boards for Bayer, Blueprint, Daiichi Sankyo, Epizyme, Fstar Therapeutics, Roche and Springworks. S.C. participated as a consultant on advisory boards for Roche, BMS, and AstraZeneca. B.R. received advisory board/consulting and honoraria fees from AstraZeneca, Regeneron, Amgen, Bayer, SITC, and Targeted Oncology. M.M.A. received advisory board/consulting and research fees from Merck, Pfizer, Bristol Myers Squibb, Foundation Medicine, Novartis, Gritstone Bio, Mirati Therapeutics, EMD Serono, AstraZeneca, Instil Bio, Regeneron, Janssen, Affini-T Therapeutics, Genentech/Roche, Lilly, Amgen. E.N. received research support from Roche, Pfizer, Bristol Myers Squibb and Merck Serono and participated as consultant in advisory boards for Amgen, AstraZeneca, Bayer, Boehringer Ingelheim, Bristol Myers Squibb, Daiichi Sankyo, Janssen, Lilly, Merck Serono, Merck Sharpe & Dohme, Pfizer, Roche, Sanofi and Takeda. E.N. participated as an investigator of clinical trials from Amgen and Revolution Medicines related to the current publication. Au.V. and A.V. are founders of the spin-off Xenopat S.L. The remaining authors declare no competing interests.
